CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program

Aug 22, 2019, 09:00 AM
The Stock Day Podcast welcomed CytoDyn (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.